Konruns Pharma's IPO plan aligned with policy

In line with Beijing's push for domestic innovation, the pharmaceutical firm aims to quintuple its product portfolio through in-house R&D and strategic acquisitions.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES